Acadesine News and Research

RSS
Acadesine is a 5-aminoimidazole-4-carboxamide (AICA) riboside, a purine nucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity.
Disappointing result for acadesine

Disappointing result for acadesine

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Generic erosion of premium-priced branded agents to offset sales of new agents

Generic erosion of premium-priced branded agents to offset sales of new agents

Ligand Pharmaceuticals and Metabasis Therapeutics enter into definitive merger agreement

Ligand Pharmaceuticals and Metabasis Therapeutics enter into definitive merger agreement

Ligand Pharmaceuticals, Metabasis Therapeutics enter into merger agreement

Ligand Pharmaceuticals, Metabasis Therapeutics enter into merger agreement

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

Schering-Plough announces licensing of Acadesine

Schering-Plough announces licensing of Acadesine